The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer.
U. Ortmann
No relevant relationships to disclose
J. Salmen
No relevant relationships to disclose
P. G. M. Hepp
No relevant relationships to disclose
M. W. Beckmann
No relevant relationships to disclose
T. N. Fehm
No relevant relationships to disclose
H. Hindenburg
No relevant relationships to disclose
W. Lichtenegger
No relevant relationships to disclose
B. K. Rack
No relevant relationships to disclose
A. Schneeweiss
No relevant relationships to disclose
W. Janni
No relevant relationships to disclose